Hot Investor Mandate: Corporate VC Arm of Global Pharmaceutical Company Invests in Breakthrough Therapeutic Platform Technologies Across the Globe

8 Sep

A corporate venture arm of a global pharmaceutical company. The firm seeks to make strategic investments into early-stage companies that are aligned with the firm’s R&D focus. For equity investments, the firm will lead, co-lead, or participate in syndicated financings.

The firm’s core focus is therapeutic platform technologies. The firm specifically targets investment opportunities that fall within the parent company’s therapeutic areas of interest: Oncology, Gastrointestinal Diseases, Neuro (non-behavioral), Rare Disease, and more. The firm is primarily interested in breakthrough platforms and is generally modality agnostic. The firm does not invest in single therapeutic assets, medical devices or diagnostics.

The firm focuses on early stage investments (Seed and Series A) in pre-clinical, therapeutic platforms. The firm invests using standard institutional venture investment terms without special rights or options.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: